Akava Therapeutics, Inc.

About Akava Therapeutics, Inc.

AKAVA Therapeutics is dedicated to discovering and developing first-in-class small molecule therapeutics that inhibit protein aggregation, enzymes, and cancer, targeting unmet medical needs in neurodegeneration and oncology to help patients live longer with improved quality of life.

Products & Services

AKV9 (Protein Aggregation Inhibitor):A lead compound identified as the first to improve the health of upper motor neurons in motor neuron diseases like ALS, PLS, HSP, and ALS/FTLD.

Ornithine Aminotransferase Inactivators:Therapeutics focused on enzyme inhibition for potential applications in neurodegenerative diseases and cancers.

Neuronal Nitric Oxide Synthase Inhibitors:Compounds aimed at inhibiting specific enzymes to address neurodegenerative conditions and other therapeutic areas.

Specialties

Neurodegenerative Diseases Oncology Protein Aggregation Inhibition Enzyme Inhibition Small Molecule Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 7300000 MR: - FA: $7.3 million FAN: 7300000	D: 2024-12-17 FD: 2024-12-17	1 investors

Grant Latest

2024-12-17

$7.3M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard B. Silverman

Inventor and Researcher

P

Philip Silverman

VP, Corporate Development and Board Member

B

Brendan MacMillan

Board Member

J

Joe Nolan

Board Member

C

Charles Polsky

Executive Board Chair

B

Bill Isaac

Former FDIC Director

View 13 more team members with Pro

Unlock Full Team Directory

Recent News